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Abstract: Non-alcoholic fatty liver disease (NAFLD) is a major health issue in developed countries.
Although usually associated with obesity, NAFLD is also diagnosed in individuals with low body
mass index (BMI) values, especially in Asia. NAFLD can progress from steatosis to non-alcoholic
steatohepatitis (NASH), which is characterized by liver damage and inflammation, leading to cirrhosis
and hepatocellular carcinoma (HCC). NAFLD development can be induced by lipid metabolism
alterations; imbalances of pro- and anti-inflammatory molecules; and changes in various other factors,
such as gut nutrient-derived signals and adipokines. Obesity-related metabolic disorders may be
improved by activation of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)β/δ,
which is involved in metabolic processes and other functions. This review is focused on research
findings related to PPARβ/δ-mediated regulation of hepatic lipid and glucose metabolism and
NAFLD development. It also discusses the potential use of pharmacological PPARβ/δ activation for
NAFLD treatment.
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is an inclusive term describing a broad range of chronic
liver pathologies [1]. During the development of this chronic condition, several potentially pathogenic
mediators are crucially involved [2]. Risk factors for NAFLD include obesity, insulin resistance,
and other features of metabolic syndrome. Steatosis is the initial benign stage, characterized by lipid
accumulation in hepatocytes due to impaired triglyceride synthesis and export, and/or reduced fatty
acid beta-oxidation. Patients with steatosis may progress to non-alcoholic steatohepatitis (NASH),
a more severe form of NAFLD that involves hepatocellular injury and liver inflammation—both
drivers of hepatic fibrosis [3]. NASH can lead to more deleterious conditions, such as cirrhosis and
hepatocellular carcinoma (HCC) [4]. NASH is rapidly becoming a leading cause of end-stage liver
disease and hepatocellular carcinoma, both of which are indications for liver transplantation [5].
As obesity rates have risen, NAFLD has become the most common chronic liver disease in humans
and is considered an epidemic disease that constitutes a major global health issue. NAFLD affects
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70% of type 2 diabetes patients, and even a greater proportion of obese diabetic individuals [6,7].
Astonishingly, NAFLD affects nearly 30% of the general population worldwide [8–10] and has
potentially serious sequelae [11]. Although steatosis is considered a relatively benign condition,
about 30% of patients with steatosis will develop NASH, and 30–40% of patients with NASH will
progress to fibrosis and cirrhosis. Among patients with cirrhosis, 4% will develop hepatocellular
carcinoma with a 10-year mortality rate of 25% [12–14].
Although the majority of affected individuals are asymptomatic, NAFLD can be detected by
ultrasound scanning or routine blood testing for elevated plasma levels of the liver enzymes alanine
aminotransferase and aspartate aminotransferase, reflecting hepatocyte injury. On the other hand,
NASH diagnosis requires a liver biopsy and histological scoring. Individuals who are diabetic or
obese, or who suffer from metabolic syndrome, should be suspected as having NAFLD and should be
examined accordingly [15–17].
Body weight reduction through increased physical activity and dietary improvement can help
with NAFLD management and delay disease progression. However, long-term lifestyle changes may
be insufficient in many cases [18–20]. Notably, there is currently no effective FDA-approved therapy
for the prevention and/or treatment of NAFLD development and progression, although several
drugs are currently being tested in clinical trials [21]. Pharmacological treatments that target insulin
resistance, including metformin and thiazolidinediones (TZDs), have been tested in NAFLD patients
and those diagnosed with NASH. These studies have not demonstrated that metformin is effective
for NAFLD treatment [21,22]. TZDs reportedly lead to decreased hepatic fat and reduced liver injury;
however, TZD discontinuation allows NASH recurrence, and long-term TZD treatment can result in
medical complications, such as congestive heart failure, osteoporosis, and weight gain in susceptible
patients [23,24]. Thus, other than weight loss, there are currently no effective interventions and
therapies for NAFLD treatment [18–21].
Peroxisome proliferator-activated receptor (PPAR)β/δ is a nuclear receptor that is closely related
to PPARγ, which is activated by TZDs, as well as to PPARα, which is targeted by hypolipidemic agents
of the fibrate class. PPARβ/δ exerts a variety of metabolic effects and physiological actions [25–29],
and PPARβ/δ activation may inhibit and improve obesity-related metabolic disorders. In the present
review, we discuss the involvement of PPARβ/δ in NAFLD, and the effects of PPARβ/δ agonists on
this pathology.
2. Hallmark of NAFLD
2.1. Two-Hit Hypothesis
It has been proposed that NAFLD pathogenesis is a “two-hit” process (Figure 1) [30,31]. In this
hypothesis, the first hit results from triglyceride accumulation in the hepatocyte cytoplasm due to
an imbalance in lipid input and output, which is the hallmark of NAFLD [30]. Four mechanisms
can contribute to triglyceride accumulation in hepatocytes: (1) upregulated free fatty acid uptake
from blood plasma in the context of increased lipolysis from adipose tissue and/or chylomicrons
after high-fat diet consumption [32]; (2) high carbohydrate uptake that increases circulating glucose
and insulin levels, thus promoting de novo lipogenesis and contributing to triglyceride accumulation
in hepatocytes [33,34]; (3) decreased fatty acid mitochondrial oxidation; and (4) reduced hepatic
triglyceride secretion via packaging of apolipoprotein B (ApoB) into very low-density lipoprotein
(VLDL) particles, promoting triglyceride accumulation in hepatocytes [33–35]. Overall, aberrations in
any lipid metabolism processes, which may involve a large number of genes, can result in NAFLD
development [36].
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Figure 1. Schematic diagram of the two-hit hypothesis of non-alcoholic fatty liver disease (NAFLD) 
progression. In the first hit, an imbalance of lipid synthesis, catabolism, and export results in lipid 
accumulation in liver (steatosis). Obesity and insulin resistance are strongly correlated with liver 
steatosis. In the second hit, further inflammation processes lead to non-alcoholic steatohepatitis 
(NASH) and fibrosis, which can evolve into more severe stages, such as cirrhosis and ultimately 
hepatocellular carcinoma. 
The second hit in this NAFLD progression model is an imbalance of pro- and anti-inflammatory 
factors, resulting in increased inflammation, as seen in NASH [30]. Hence, the most critical and 
challenging step in NAFLD progression is the transition from relatively benign steatosis to the 
damaged and inflamed liver in NASH. Any strong chronic inflammation will cause fibrosis, thereby 
contributing to the development of cirrhosis and eventually hepatocellular carcinoma [37]. 
2.2. Multiple Parallel Hit Hypothesis 
The multiple parallel hit hypothesis considers alterations in the regulation of several factors, 
including gut nutrient-derived signals, adipokines, and certain pro-inflammatory cytokines (Figure 
2) [38]. Insulin resistance leads to alterations of nutrient metabolism and is thus commonly associated 
with NAFLD development [39]. Elevated levels of inflammatory cytokines, such as interleukin 6 (IL6) 
and tumor necrosis factor α (TNFα), result in hepatic inflammation [40]. The administration of TNFα 
antibody into ob/ob mice induces steatosis improvement, supporting a role of TNFα in NAFLD 
progression. Moreover, hepatic steatosis can be induced through primary inflammation in ob/ob mice 
[41]. In humans, inflammation is occasionally observed before steatosis, as seen in patients who have 
NASH but exhibit lower levels of steatosis [42]. 
Genome-wide association studies (GWAS) have identified genes that are involved in diseases 
and that can be targeted for disease treatments. A GWAS of various races found that NAFLD was 
linked to a polymorphism in the patatin-like phospholipase domain containing 3 (PNPLA3) gene [43]. 
PNPLA3 is a multifunctional enzyme involved in triacylglycerol hydrolysis and acyl-CoA-
independent transacylation of acylglycerols [44]. The nonsynonymous rs738409 C/G variant in 
PNPLA3 encodes I148M. It is proposed to be the main genetic component of NAFLD and NASH [45]. 
It reportedly shows the strongest risk effect on NAFLD development, accounting for 5.3% of total 
variance, and is associated with histological disease severity and NAFLD progression [45,46]. In 
patients with the single PNPLA3 nucleotide polymorphism rs738409 G/G, fatty liver progresses 
directly to NASH [47,48]. Notably, mice with Pnpla3 deficiency do not develop fatty liver or liver 
injury [49], and Pnpla3 knockdown decreases intracellular triglyceride levels in primary hepatocyte 
cultures [50]. Thus, the function of PNPLA3 in NAFLD warrants further investigation. Interestingly, 
Pnpla3 is a downstream target gene of sterol-regulated binding protein 1c (SREBP1c) and can mediate 
its effect in promoting lipid accumulation. Therefore, PNPLA3 has been suggested as a possible “first 
hit”, preceding other hits that may affect disease progression [51]. 
Figure 1. Schematic diagram of the two-hit hy is of non-alcoholic fatty liver disease (NAFLD)
progression. I the first hit, an imbalance of li i s thesis, catabolism, and export results in lipid
accumulation in liver (steatosis). Obesity and insulin resistance are strongly correlated with liver
steatosis. In the second hit, further inflammation processes lead to non-alcoholic steatohepatitis
(NASH) and fibrosis, which can evolve into more severe stages, such as cirrhosis and ultimately
hepatocellular carcinoma.
The second hit in this NAFLD progression model s an imbalance of pro- and anti- nflammatory
factors, resulting in i creased inflammation, as seen in NASH [30]. Hence, the most critical and
challenging step in NAFLD progression is the transition from relatively benign steatosis to the damaged
and inflamed liver in NASH. Any strong chronic inflammation will cause fibrosis, thereby contributing
to the development of cirrhosis and eventually hepatocellular carcinoma [37].
2.2. Multiple Parallel Hit Hypot esis
The multiple parallel hit hypothesis considers alterations in the regulation of several factors,
including gut nutrient-derived signals, adipokines, and certain pro-inflammatory cytokines
(Figure 2) [38]. Insulin resistance lead to alterations of nutrient metabolis and is thus commonly
associated with NAFLD dev lopment [39]. Elevated le ls of inflammatory cytokines, such as interleukin 6
(IL6) and tum r necrosis factor α (TNFα), result in hepatic inflam tion [40]. The administration of
TNFα antibody into ob/ob ice induces steatosis improvement, supporting a role of TNFα in NAFLD
progression. Moreover, hepatic steatosis can be induced through primary inflammation in ob/ob
mice [41]. In humans, inflammation is occasionally observed before steatosis, as seen in patients who
have NASH but exhibit lower levels of steatosis [42].
Genome-wide association studies (GWAS) have identified genes that are involved in diseases
and that can be targeted for disease treatments. A GWAS of various races found that NAFLD was
linked to a polymorphism in the patatin-like p ospholipase d ain containing 3 (PNPL 3) gene [43].
PNPLA3 is a multifunctional enzyme involved i triacylglycerol hydrolysis a d acyl-CoA-independent
transacylation of acylglycerols [44]. The nonsynonymous rs738409 C/G variant in PNPLA3 encodes
I148M. It is proposed to be the main genetic component of NAFLD and NASH [45]. It reportedly shows
the strongest risk effect on NAFLD development, accounting for 5.3% of total variance, and is associated
with histological disease severity and NAFLD progression [45,46]. In patients with the single PNPLA3
nucleotide polymorphism rs738409 G/G, fatty liver progresses directly to NASH [47,48]. Notably,
mice with Pnpla3 deficiency do not develop fatty liver or liver injury [49], and Pnpla3 knockdown
decreases intracellular triglyceride levels in primary hepatocyte cultures [50]. Thus, the function
of PNPLA3 in NAFLD warrants further investigation. Interestingly, Pnpla3 is a downstream target
gene of sterol-regulated binding protein 1c (SREBP1c) and can mediate its effect in promoting lipid
accumulation. Therefore, PNPLA3 has been suggested as a possible “first hit”, preceding other hits
that may affect disease progression [51].
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Figure 2. Schematic illustration of the multiple parallel hits hypothesis of NAFLD development. 
NAFLD develops due to the impaired regulation of several factors, such as gut nutrient-derived 
signals, adipokines, and certain pro-inflammatory cytokines. 
Two other widely studied genetic modifiers of NAFLD are the transmembrane 6 superfamily 
member 2 (TM6SF2) and glucokinase regulator (GCKR) genes. TM6SF2 regulates liver fat 
metabolism, influencing triglyceride secretion and hepatic lipid droplet content [52]. The 
nonsynonymous rs58542926 variant in TM6SF2 encodes E167K and is associated with increased liver 
fat levels [53]. Patients with NAFLD show significantly lower TM6SF2 expression in the liver [54]. 
With regards to NAFLD risk alleles of TM6SF2, the C (Glu167) allele is correlated with higher 
cardiovascular risk via elevated circulating low-density lipoprotein (LDL)-cholesterol levels [55], and 
the T (Lys167) allele is associated with NAFLD and NASH [54,56,57]. GCKR encodes the glucokinase 
regulatory protein, which controls the activity and intracellular location of glucokinase, a key enzyme 
in glucose metabolism [58]. The GCKR missense variant rs780094 is significantly associated with 
histological NAFLD [59,60]. Moreover, GCKR mutations reportedly cause maturity-onset diabetes in 
young individuals with NAFLD risk factors, such as glucose intolerance and insulin resistance [61]. 
Histological NAFLD is also significantly associated with variants in or near the neurocan (NCAN) 
and lysophospholipase like 1 (LYPLAL1), but not protein phosphatase 1 regulatory subunit 3B 
(PPP1R3B) genes [59]. 
Obesity is another increasingly common global condition that is associated with diseases, 
including NAFLD, hypertension, type 2 diabetes mellitus, and hyperlipidemia. In fact, hypertension, 
hypertriglyceridemia, and obesity are predictive risk factors for NAFLD [62]. Over the past decade, 
visceral obesity has become more common among adults and children worldwide in association with 
increased consumption of Western-style diets with high fat and fructose contents [63]. Visceral fat 
accumulation is positively correlated with various organ pathologies, including NAFLD, as well as 
with insulin resistance in both obese and non-obese individuals. These findings suggest that visceral 
fat accumulation influences hepatic steatosis, regardless of the degree of obesity [64]. 
3. Peroxisome Proliferator-Activated Receptor β/δ Expression in Liver 
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor 
superfamily, which comprises ligand-activated transcription factors. PPARs play important roles in 
regulating genes involved in fatty acid uptake and oxidation, lipid and carbohydrate metabolism, 
Figure 2. Schematic illustration of the multiple parallel hits hypothesis of NAFLD development.
NAFLD develops due to the impaired regulation of several factors, such as gut nutrient-derived signals,
adipokines, and certain pro-inflammatory cytokines.
Two other widely studied genetic modifiers of NAFLD are the transmembrane 6 superfamily
member 2 (TM6SF2) and glucokinase regulator (GCKR) genes. TM6SF2 regulates liver fat metabolism,
influencing triglyceride secretion and hepatic lipid droplet content [52]. The nonsynonymous
rs58542926 variant in TM6SF2 encodes E167K and is associated with increased liver fat levels [53].
Patients with NAFLD show significantly lower TM6SF2 expression in the liver [54]. With regards
to NAFLD risk alleles of TM6SF2, the C (Glu167) allele is correlated with higher cardiovascular
risk via elevated circulating low-density lipoprotein (LDL)-cholesterol levels [55], and the T (Lys167)
allele is associated with NAFLD and NASH [54,56,57]. GCKR encodes the glucokinase regulatory
protein, which controls the activity and intracellular location of glucokinase, a key enzyme in
glucose metabolism [58]. The GCKR missense variant rs780094 is significantly associated with
histological NAFLD [59,60]. Moreover, GCKR mutations reportedly cause maturity-onset diabetes in
young individuals with NAFLD risk factors, such as glucose intolerance and insulin resistance [61].
Histological NAFLD is also significantly associated with variants in or near the neurocan (NCAN) and
lysophospholipase like 1 (LYPLAL1), but not protein phosphatase 1 regulatory subunit 3B (PPP1R3B)
genes [59].
Obesity is another increasingly common global condition that is associated with diseases,
including NAFLD, hypertension, type 2 diabetes mellitus, and hyperlipidemia. In fact, hypertension,
hypertriglyceridemia, and obesity are predictive risk factors for NAFLD [62]. Over the past decade,
visceral obesity has become more common among adults and children worldwide in association with
increased consumption of Western-style diets with high fat and fructose contents [63]. Visceral fat
accumulation is positively correlated with various organ pathologies, including NAFLD, as well as
with insulin resistance in both obese and non-obese individuals. These findings suggest that visceral
fat accumulation influences hepatic steatosis, regardless of the degree of obesity [64].
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3. Peroxisome Proliferator-Activated Receptor β/δ Expression in Liver
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor
superfamily, which comprises ligand-activated transcription factors. PPARs play important roles in
regulating genes involved in fatty acid uptake and oxidation, lipid and carbohydrate metabolism,
vascular biology, inflammation, cell proliferation, and senescence [65–67]. To be transcriptionally
active, PPARs must heterodimerize with the 9-cis retinoic acid receptor (RXR) (Figure 3) [68].
If an agonist is absent or in the presence of an antagonist, the PPAR-RXR heterodimer associates
with co-repressor proteins. This complex occupies the promoter region within a subset of PPAR target
genes, and consequently blocks their transcription. Such co-repressor proteins include the well-known
silencing mediator of retinoid and thyroid receptors (SMRT), and the nuclear receptor corepressor
(NCoR) [68–70].
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heterodimer binds the peroxisome proliferator response element (PPRE) and stimulates target gene 
transcription (Transactivation). In macrophages, endothelial cells, and vascular smooth muscles, in 
the absence of a PPARβ/δ agonist or ligand, the receptor will scavenge BCL-6 (a PPARβ/δ-associated 
transcriptional repressor). Once PPARβ/δ neutralizes BCL-6, transcription factors (TFs) bind to TF-
binding sites (TFBSs), allows transcription of the genes repressed by BCL-6. However, the binding of 
a PPARβ/δ ligand to PPARβ/δ will result in BCL-6 dissociation, leading to co-repressor-dependent 
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On the other hand, in the presence of an agonist, PPAR activation results in an exchange within 
the co-regulator complex. This involves co-activator recruitment upon co-repressor dissociation. 
Activated PPAR-RXR heterodimers bind to peroxisome proliferator response elements (PPREs) 
located in the regulatory regions (5′-end region and introns) of PPAR target genes [68,71,72]. This 
results in altered expression levels of PPAR target genes. PPAR and RXR bind to the 5′ and 3′ half-
sites of the PPRE, respectively [73]. The 5′ flanking region of the PPRE contributes to the selectivity 
of binding of the different PPAR isotypes [74], but the selection of the PPAR target genes to be 
activated by a given PPAR isotype in vivo is not yet well understood. It is thought that it results from 
Figure 3. Regulatory mechanisms of gene transcription by peroxisome proliferator-activated receptors
(PPARs). Each PPAR structurally comprises an N-terminal domain (NTD), a DNA-binding domain
(DBD), and a ligand-binding domain (LBD). In the absence of a ligand or in the presence of an antagonist,
the PPAR-RXR heterodimer associates with nuclear receptor co-repressor proteins, leading to repression
of PPAR target genes (Repression). Fatty acid-binding protein (FABP) associates with the ligand/agonist
to transport it into the cell. Upon ligand binding, a conformational change in PPAR leads to
co-repressor dissociation, and co-activators are recruited. The activated PPAR-RXR heterodimer
binds the peroxisome proliferator response element (PPRE) and stimulates target gene transcription
(Transactivation). In macrophages, endothelial cells, and vascular smooth muscles, in the absence of a
PPARβ/δ agonist or ligand, the receptor will scavenge BCL-6 (a PPARβ/δ-associated transcriptional
repressor). Once PPARβ/δ neutralizes BCL-6, transcription factors (TFs) bind to TF-binding sites
(TFBSs), allows transcription of the genes repressed by BCL-6. However, the binding of a PPARβ/δ
ligand to PPARβ/δ will result in BCL-6 dissociation, leading to co-repressor-dependent transre ression
of BCL-6 targeted genes, such as b6rg, which encodes a sequence-specific transcriptio repr ssor
(Transrepression). The dashed arrow with a question mark indic tes that it is not known how the
antagonist is translocated to the cell ucleus. The curvy arrow indicates the dissociation of t
co-repressor from the transcription factor.
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On the other hand, in the presence of an agonist, PPAR activation results in an exchange within
the co-regulator complex. This involves co-activator recruitment upon co-repressor dissociation.
Activated PPAR-RXR heterodimers bind to peroxisome proliferator response elements (PPREs) located
in the regulatory regions (5′-end region and introns) of PPAR target genes [68,71,72]. This results in
altered expression levels of PPAR target genes. PPAR and RXR bind to the 5′ and 3′ half-sites of the
PPRE, respectively [73]. The 5′ flanking region of the PPRE contributes to the selectivity of binding
of the different PPAR isotypes [74], but the selection of the PPAR target genes to be activated by
a given PPAR isotype in vivo is not yet well understood. It is thought that it results from a complex
interplay between expression levels of the three isotypes in the cell, ligand and cofactor availability,
affinity for a given PPRE, and probably factors binding in the vicinity of the PPRE [72]. Comprehensive
studies integrating expression profiling and genome-wide promoter binding by the PPARs are required
to better understand the promoter-specific mechanisms of PPAR action. Interestingly, PPAR/RXR
heterodimers can induce transcription in response to PPAR or RXR ligand-dependent activation
and the relative levels of cofactor expression are important determinants of the specificity of the
physiological responses to PPAR or RXR agonists [72]. Studies of PPARs’ roles in reducing the
expression of a subset of inflammatory response genes have highlighted a repressive molecular mode
of action, termed transrepression, through which PPARs impact key transcription factor activity.
Transrepression occurs through tethering, in which direct protein–protein interactions inhibit the
binding of transcription factors to DNA. The regulation of gene transcription by PPAR can also take
place through the sequestration of coactivators or the release of corepressors, which stimulates and
represses promoter activity, respectively (Figure 3) [72].
The PPAR family includes three isotypes—PPARα, PPARβ/δ, and PPARγ—which have the
canonical nuclear receptor domain organization [68,75]. The N-terminal A/B domain possesses a weak
ligand-independent transactivation function known as activation function (AF)-1. The C domain
binds DNA via two zinc-finger motifs, and the D domain is a hinge region. The E domain contains
the ligand-binding domain (LBD), possesses the ligand-dependent transactivation function termed
AF-2, and includes the region for dimerization and interaction with regulatory proteins [76,77].
PPARβ/δ also functions in the regulation of gene expression independently of DNA binding,
through cross-talk with other transcription factors, which consequently influences their transrepressor
function. For example, PPARβ/δ associates with the transcriptional repressor B-cell lymphoma-6
(BCL-6) (Figure 3) in macrophages, endothelial cells, and vascular smooth muscle cells [78,79].
In the presence of a PPARβ/δ agonist, BCL-6 dissociates from PPARβ/δ and subsequently binds
to promoter regions of pro-inflammatory genes, such as vascular cell adhesion molecule-1 (VCAM-1)
and E-selectin. With the aid of a co-repressor complex, such binding will repress the transcription of
these genes [29,80,81].
4. Hepatic Functions of PPARβ/δ Compared to PPARα and PPARγ
As mentioned above, Pparα, Pparβ/δ, and Pparγ encode proteins with a highly conserved structure
and molecular mode of action. However, the receptors differ in their tissue distribution patterns and
target genes and, therefore, in the biological functions that they regulate. Below, we briefly review the
roles of PPARα and PPARγ, and then discuss those of PPARβ/δ in greater detail.
4.1. PPARα
PPARα is predominantly expressed in tissues with high levels of fatty acid catabolism, including
the liver, as well as brown adipose tissue, heart, kidney, and skeletal muscle [82–84]. In the liver, PPARα
is involved in fatty acid metabolism through transcriptional upregulation of numerous genes that play
roles in mitochondrial and peroxisomal fatty acid oxidation, and in phospholipid remodeling [85–87].
PPARα also participates in downregulating hepatic inflammatory processes by reducing the effects of
acute exposure to cytokines [88–91].
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Preclinical and clinical studies have demonstrated that PPARα can influence NAFLD and
NASH development [92–97]. Fasting is sufficient to trigger steatosis in PPARα-null mice, indicating
that PPARα activity is required for metabolizing free fatty acids released from adipocytes [98,99].
Since PPARα is expressed and active in many organs, it is possible that the absence of PPARα in these
organs might contribute to the development of fasting-induced steatosis. Therefore, we generated
a hepatocyte-specific Pparα-null mouse and found that hepatocyte-restricted Pparα deletion is sufficient
to promote steatosis [97]. This mouse shows impaired whole-body fatty acid homeostasis not only
during fasting, but also when fed a methionine- and choline-deficient diet or a high-fat diet. Collectively,
these data establish PPARα as a relevant drug target in NAFLD [97].
4.2. PPARγ
The PPARγ protein has two isoforms: PPARγ1 and PPARγ2. Differential promoter usage
and alternate splicing of the PPARγ gene products actually generate three messenger RNAs
(mRNAs)—PPARγ1, PPARγ2, and PPARγ3—with the PPARγ1 and PPARγ3 mRNAs both encoding
the PPARγ1 protein [100]. PPARγ isoforms γ1 and γ2 are highly expressed in white and brown
adipose tissues, where the receptor governs adipocyte differentiation and lipid storage. PPARγ1 is
also expressed in the brain, vascular cells, colon, and immune cells [82,83].
PPARγ is weakly expressed in healthy liver, and steatosis is associated with increased hepatic
expression of the PPARγ2 isoform, as observed in various mouse models of obesity [101,102].
Accordingly, hepatocyte-specific PPARγ deletion reduces hepatic fat content in mice fed a high-fat
diet [103]. Increased PPARγ2 gene expression is also positively correlated with liver steatosis in
obese patients [104,105]. Findings in the hepatocyte-specific PPARγ-knockout model indicated that
PPARγ directly promotes hepatic fat accumulation by increasing lipid uptake, and by promoting
de novo lipogenesis [106–110]. More recently, observations in an original mouse model of inducible
hepatocyte-specific PPARγ deletion have suggested that PPARγ plays a specific role in fatty acid uptake
and diacylglycerol (DAG) synthesis via upregulation of Cd36 and monoacylglycerol O-acyltransferase 1
(Mogat1) [111]. Moreover, PPARγ plays important roles in glucose metabolism by regulating the
expression of hexokinase 2 (HK2) and the M2 isoform of pyruvate kinase (PKM2), resulting in massive
liver steatosis in phosphatase and tensin homologs deleted on chromosome 10 (PTEN)-null mice [112].
4.3. PPARβ/δ
PPARβ/δ is ubiquitously expressed, with the expression level varying among organs, cells,
and species. Hepatic expression is low to moderate in adult humans and rats [82,113–116] and moderate
to high in mice [117]. Pparβ/δ is highly expressed in hepatocytes, liver sinusoidal endothelial cells
(LSECs), and liver-resident macrophages (Kupffer cells) [118]. Pparβ/δ expression is also constitutively
high in hepatic stellate cells (HSCs).
In liver tissue of Pparβ/δ-null mice, transcriptional profiling revealed downregulation of genes
associated with lipoprotein metabolism and glucose utilization pathways, indicating that these genes
are positively regulated by PPARβ/δ. On the other hand, genes involved in innate immunity and
inflammation were upregulated, suggesting their repression by PPARβ/δ. These transcriptional
changes in Pparβ/δ-null mice correlated with increased plasma glucose and triglyceride levels,
and reduced plasma cholesterol levels [119]. These results suggested important roles of PPARβ/δ in
energy metabolism and inflammation, which we discuss below.
4.3.1. PPARβ/δ Roles in Energy Metabolism
In a very informative piece of work, Liu et al. demonstrated that adenovirus-mediated liver-restricted
PPARβ/δ overexpression reduced fasting glucose levels in both chow- and high fat-fed mice.
In parallel an increased hepatic glycogen and lipid deposition was observed accompanied by an
up-regulation of glucose utilization and de novo lipogenesis [28]. PPARβ/δ increased the production
of monounsaturated fatty acids (MUFAs), which activate PPARs, while reducing saturated fatty acid
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levels. Lipid accumulation in the adeno-PPARβ/δ-infected livers reduced cell damage and c-Jun
N-terminal kinase (JNK) stress signaling. The authors proposed that the PPARβ/δ-regulated lipogenic
program may protect against lipotoxicity, and that altered substrate utilization by PPARβ/δ resulted
in AMP-activated protein kinase activation, which may contribute to the glucose-lowering activity
of PPARβ/δ. Taken together, this data suggested that PPARβ/δ impacts hepatic energy substrate
homeostasis by a coordinated control of fatty acid and glucose metabolism [28].
In line with these findings, PPARβ/δ regulates lipogenic genes during the dark/feeding cycle.
Specifically, PPARβ/δ drives MUFA production via stearoyl-CoA desaturase 1 (Scd1) upregulation,
a process that avoids lipotoxicity by increasing fatty acid oxidation or sequestration of saturated
fatty acids. As such, the process inhibits saturated fatty acid-induced cytotoxicity in hepatocytes.
Furthermore, long chain acyl-CoA from MUFA production allows esterification into triglycerides [120].
Interestingly, liver-specific PPARβ/δ activation increases fatty acid uptake in muscle, whereas its
deletion has an opposite effect. Phosphatidylcholine 18:0/18:1 (PC (18:0/18:1)) was identified as a
serum lipid produced in the liver under the control of PPARβ/δ activity, which upon circulating to
muscles stimulates fatty acid catabolism through PPARα activation [121].
For a direct comparison of the roles of Pparα and Pparβ/δ in liver, microarray analysis was
being used to compare the liver transcriptome between Pparα and Pparβ/δ-null mice, revealing a
small overlap in the regulation of genes that are both PPARα- and PPARβ/δ-dependent. In the fed
state, similar numbers of genes exhibited altered expression in Pparα and Pparβ/δ deletion. However,
during fasting, more genes showed altered expression in Pparα-deleted mice compared to Pparβ/δ-null
mice. Analysis of plasma metabolites, including free fatty acids and β-hydroxybutyrate, supported the
notion that PPARα is particularly important during fasting, while PPARβ/δ appears to be important
in both the fed and fasted states [119]. Based on functional similarities to PPARα, PPARβ/δ may be a
master regulator of hepatic intermediary metabolism. In rodents, both receptors play non-redundant
roles in the liver to enhance ketogenesis through induction of Fgf21 and expression of fatty acid
oxidation genes under fasting conditions [122,123]. In fact, PPARα is an important activator of hepatic
fatty acid oxidation [97,99,124]. Interestingly, PPARβ/δ cannot compensate for PPARα in Pparα-null
mice [98].
The differences between PPARα and PPARβ/δ in molecular and biological functions also
corresponded with their antiphasic circadian expression profiles. Indeed, PPARα peaks at the end the
light/resting period, while PPARβ/δ is highly expressed in the liver during the night/feeding period,
according to [86,121], and Montagner et al., unpublished results. Notably, during fasting (usually
light period), PPARβ/δ expression decreases while PPARα is highly expressed [125]. In spite of their
biphasic expression profile, intra- and inter-organ dialogs between PPARβ/δ and PPARα activities have
been described. As mentioned above, increased hepatic PPARβ/δ activity can lead to PPARα activation
in muscle tissue via production of the specific PPARα ligand 16:0/18:1-phosphatidylcholine [121].
This mechanism could also occur in the liver [121,126]. Overall, while both PPARα and PPARβ/δ are
associated with the regulation of hepatic lipid metabolism [127,128], hepatic PPARβ/δ mainly acts
on anabolic metabolic processes and primarily contributes to glucose utilization, MUFA formation,
and anti-inflammatory responses [119,129].
Compared with PPARα and PPARγ, less is known about PPARβ/δ in relation to obesity and
NAFLD [130]. However, the lipogenic activity of PPARβ/δ raises the question of whether PPARβ/δ
activation is associated with steatosis and steatohepatitis. It was recently shown that both PPARβ/δ
and PPARα receptors were necessary for adipose tissue reduction driven by the PPARβ/δ agonist
GW501516 and subsequent development of hepatic steatosis, with PPARβ/δ working upstream of
PPARα [131]. PPARβ/δ is also involved in transforming potentially toxic lipids into less toxic molecules
by regulating MUFA synthesis, a process that increases PPARα activity and could protect against
NAFLD and promote detoxification. In mice with adenovirus-mediated liver-restricted PPARβ/δ
overexpression, examination revealed elevated liver expression of the adiponectin receptor 2 (AdipoR2),
leading to enhanced 5′ adenosine monophosphate-activated protein kinase (AMPK) activity [132].
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This PPARβ/δ-dependent increase in AMPK activity reportedly suppressed lipogenesis and glycogen
synthesis, reduced gluconeogenesis, and increased fatty acid oxidation [25–27]. The AMPK pathway
may act as a negative feedback loop for PPARβ/δ, possibly explaining why long-term PPARβ/δ
agonist treatment does not lead to liver lipid accumulation [133]. Similarly, PPARβ/δ suppresses
lipogenesis by lowering SREBP1c levels, reducing the severity of hepatic steatosis in obese diabetic
db/db mice via stimulation of the insulin-induced gene-1 (Insig-1), the product of which inhibits
SREBP1c [134].
Fibroblast growth factor 21 (FGF21) is a circulating hormone derived from the liver, which plays
important roles in regulating glucose and lipid metabolism [135,136]. Recent evidence shows that
PPARβ/δ and FGF21 exert hepatic regulation of the VLDL receptor, which modulates NAFLD.
Liver tissue of Pparβ/δ-null mice and Pparβ/δ−/− hepatocytes exhibit increased VLDL receptor
expression. Moreover, FGF21 neutralizing antibody treatment resulted in triglyceride accumulation
in Pparβ/δ-null mice [137]. In support of these pre-clinical results, liver biopsies from patients with
moderate and severe hepatic steatosis showed increased VLDL receptor levels and reduced PPARβ/δ
mRNA levels and DNA-binding activity compared to in control subjects. These findings revealed a
novel mechanism in which VLDL receptor levels are controlled by PPARβ/δ and FGF21, impacting
hepatic steatosis development [137].
4.3.2. PPARβ/δ Roles in Inflammation
On a high-fat diet, the PPARβ/δ-dependent increase in hepatocyte MUFA production impacts
liver-resident macrophages and Kupffer cells—resulting in increased PPARβ/δ activation, and reduced
expression of TNFα or interferon gamma (IFNγ) inflammatory markers from these cells—and altering
the immune response [28]. Thus, this finding suggests that PPARβ/δ plays an anti-inflammatory role
in liver. PPARβ/δ and its ligands are also reportedly associated with anti-inflammatory activities
through interference with nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB)
signaling [67,138,139] and through interactions with signal transducer and activator of transcription 3
(STAT3) and extracellular-signal-regulated kinase 5 (ERK5) [140,141].
Kupffer cells are also involved in insulin resistance and fatty liver disease [142], and PPARβ/δ
plays a role in regulating the alternative activation of these cells [143]. In the presence of IL4 and
IL13 stimulation, PPARβ/δ is required for the activation of Kupffer cells to the M2 subtype that
has anti-inflammatory activity. Hematopoietic Pparβ/δ-deficient obese mice exhibited lower insulin
sensitivity and oxidative metabolism, as well as impaired alternative activation of Kupffer cells.
This phenotype was validated by three independent lines of experiments. First, Pparβ/δ deletion in
lean mice resulted in lower expression of genes involved in alternatively activated Kupffer cells, such as
arginase 1 (Arg1), c-type lectin domain containing 7A (Clec7a), jagged 1 (Jag1), programmed cell death
1 ligand 2 (Pdcd1lg2) and chitinase (Chia). However, treatment with PPARβ/δ agonist GW0742 led
to increased expression of these genes in liver. Second, replacing the bone marrow of wild-type mice
with Pparβ/δ-null bone marrow led to insulin resistance and mitochondrial dysfunction in hepatocytes,
eliminating the alternative activation of Kupffer cells. Third, direct co-culturing of Pparβ/δ-null
macrophages with primary hepatocytes induced a significant reduction of oxidative phosphorylation
in the parenchymal cells. The study demonstrated the association between Pparβ/δ-null Kupffer cells
and dysregulation of hepatic metabolism, resulting in increased liver triglycerides [143].
PPARβ/δ is also involved in hepatic stellate cell (HSC) activation; its expression is upregulated
in cultures of activated HSCs and in in vivo fibrogenesis [144,145]. Administration of the PPARβ/δ
agonist L165041 enhances HSC proliferation, and L165041 administration combined with chronic
carbon tetrachloride (CCl4) treatment leads to higher fibrotic marker expression in rats [146]. These data
suggested that PPARβ/δ plays an important role as a signal-transducing factor, leading to HSC
proliferation in the event of acute and chronic liver inflammation [146]. In activated HSCs, PPARβ/δ
enhances the expression of Cd36, which codes for a membrane receptor that facilitates fatty acid
uptake. Moreover, upregulated PPARβ/δ expression is associated with elevated expression of proteins
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involved in retinoid binding and esterification, such as cellular retinol-binding protein 1 (CRBP-1) and
lecithin retinol acyltransferase (LRAT). Overall, PPARβ/δ regulates the expression of genes related to
vitamin A metabolism in HSCs undergoing activation [144].
Interestingly, CCl4-induced hepatic fibrotic response requires PPARβ/δ which enhances expression
of profibrotic and pro-inflammatory genes in mice. This process results in increased macrophage
recruitment and extracellular matrix deposition in the liver [145]. However, this phenotype was not
observed in Pparβ/δ-null mice treated with CCl4 alone or with CCl4 plus GW501516. The same study
further demonstrated that GW501516 administration increased HSC proliferation in CCl4-injured
wild-type mice livers, but not in Pparβ/δ-null mice with the same treatment. In another study,
GW501516-treated db/db mice exhibited higher expression of the lipogenic enzyme acetyl-CoA
carboxylase β and elevated triglyceride levels in the liver [147]. Moreover, investigations of
GW501516 treatment in control and Pparβ/δ-knockdown LX-2 human hepatic stellate cells revealed
that GW501516-stimulated HSC proliferation occurs via p38 and JNK mitogen-activated protein kinase
(MAPK) pathways [145]. However, in the same model of CCl4-induced liver damage, administration
of the PPARβ/δ agonist KD3010 (chemical abstracts service, CAS ID 934760-90-4) ameliorated the
CCl4-induced liver injury with lower deposition of extracellular matrix proteins. KD3010 treatment
of primary hepatocytes provided protection from CCl4-induced cell death or starvation, suggesting
that KD3010 administration could have hepatoprotective and antifibrotic effects in animal models
of liver fibrosis [148]. Further studies are needed to determine the reasons for the different effects of
GW501516 and KD3010 in injured livers [149].
In mice treated with the agonist GW0742, NFκB signaling was attenuated in a PPARβ/δ-dependent
manner. Compared to wild-type mice, Pparβ/δ-null mice exhibited higher TNFα and αSMA expression
in hepatocytes and HSCs, but similar inflammatory signaling in hepatocytes and activation of
HSCs [150]. A recent study using the same PPARβ/δ agonist demonstrated that PPARβ/δ upregulates
serum high-density lipoprotein (HDL) and HDL phospholipids in NAFLD mice, while this effect is
not seen in Pparβ/δ-deficient mice [151].
5. Pharmacological Strategies Targeting PPARβ/δ for NAFLD Treatment
5.1. PPARβ/δ Agonists: GW0742, GW501516
Preclinical studies have investigated long-term treatment with PPARβ/δ agonists such as GW0742
(CAS ID 317318-84-6) and GW501516 (CAS ID 317318-70-0) in animal models, revealing that PPARβ/δ
activation attenuates hepatic steatosis by promoting fatty acid oxidation, reducing lipogenesis,
and enhancing insulin sensitivity [134,152–154]. On the contrary, short-term treatment with PPARβ/δ
agonists reportedly yields a transient increase in hepatic triglyceride levels [131]. Elevated levels of
monounsaturated fatty acids, are accompanied by lower saturated fatty acid levels and no observed
hepatotoxicity [28]. Studies involving PPARβ/δ agonist treatment in humans have demonstrated
reduced hepatic fat content and improved plasma markers of liver function, including carnitine
palmitoyltransferase 1b [155,156]. One study conducted in middle-overweight patients revealed
that GW501516 treatment decreased liver lipid content and insulinemia, with no signs of oxidative
stress [156]. However, LDL cholesterol plasma level was also reduced. This suggests that the protective
effects of PPARβ/δ pharmacological activation are reliant on increased lipid oxidation in muscles.
5.2. PPAR Dual Agonists: Elafibranor, Saroglitazar
The PPARα and PPARβ/δ dual agonist elafibranor (also known as GTF-505, CAS ID 923978-27-2)
has recently emerged as one of the most promising chemical entities for treatment of NAFLD,
especially NASH. Prior studies have demonstrated its efficiency, and it is currently undergoing
phase III testing in NASH patients. It has reportedly improved steatosis, inflammation, and fibrosis
in mouse models of NAFLD [95], and thus appears to be a good candidate for the treatment of
hepatic fibrosis, NAFLD, primary biliary cirrhosis, and NASH. Elafibranor was investigated in a
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randomized, double-blind, placebo-controlled trial including 274 patients in Europe and the USA
(GOLDEN-505 trial; NCT01694849). Post-hoc analysis of those trial results revealed that ALT was
significantly reduced after four to 12 weeks of elafibranor treatment among patients who were in
the top two quartiles at baseline. Non-cirrhotic patients with NASH did not exhibit any worsening
of hepatic fibrosis after 52 weeks of taking elafibranor at 120 mg/day [157]. Liver biopsy analysis
in this patient group further revealed disappearance of hepatocellular ballooning, with no or mild
lobular inflammation. Elafibranor-treated patients also exhibited improvement in liver enzymes, lipid
parameters (triglycerides, low-density lipoprotein, high-density lipoprotein, and cholesterol), serum
inflammation biomarkers, steatosis, and fibrosis. Other studies have reported that elafibranor treatment
improves glucose homeostasis and insulin resistance in diabetic patients [157,158]. Overall, elafibranor
appears to be safe and well-tolerated, with no deaths or cardiovascular incidents reported during
treatment. There is currently an ongoing phase III randomized, double-blind, placebo-controlled trial
of elafibranor use in 2000 liver biopsy-proven NASH patients, to investigate the efficacy against NASH
and the safety regarding fibrosis during longer use (72 weeks) (NCT02704403) [159].
Interestingly, the PPARα/γ dual agonist saroglitazar (CAS ID 495399-09-2) has also exhibited overall
beneficial effects in experimental models of NASH [160]. Moreover, saroglitazar treatment induces a
significant decrease of ALT levels in subjects with biopsy-proven NASH [21]. Since saroglitazar improves
all of the components responsible for NAFLD/NASH in preclinical models, it is also a promising
candidate for the management of these conditions. Further studies are needed to examine the possible
common and different pathways of action of elafibranor and saroglitazar.
5.3. PPAR Pan-Agonists: Bezafibrate, MHY2013, Lanifibranor
The anti-fibrotic and anti-inflammatory effects of PPARs have inspired growing use of PPAR
pan-agonists to treat NAFLD. It is postulated that PPAR pan-agonist may show improved efficacy
compared to targeting a single PPAR isotype [161]. The PPAR pan-agonist bezafibrate (CAS ID 41859-67-0),
which activates PPARα, PPARβ/δ, and PPARγ, has shown beneficial effects in NASH treatment.
In mice fed a methionine- and choline-deficient diet, bezafibrate and GW501516 (selective PPARβ/δ
agonist) treatments have resulted in upregulation of β-oxidation and lipid transport genes in
hepatocytes. They have inhibited NASH development. These treatments also both resulted in reduced
inflammatory gene expression [152]. MHY2013 is another PPAR pan-agonist that also activates all
three PPAR isotypes. In aged Sprague-Dawley (SD) rats, MHY2013 treatment improved age-related
hepatic lipid accumulation, and resulted in upregulated β-oxidation signaling and lower inflammation
in the liver [162]. The PPAR pan-agonist Lanifibranor (CAS ID 927961-18-0) is reportedly effective in
experimental skin and lung fibrosis [163,164]. It has been proposed for use as an anti-fibrotic treatment.
Lanifibranor is currently being tested in a phase 2b randomized, double-blind, placebo-controlled trial
for safety and efficacy in up to 225 patients in 12 European countries (NCT03008070) [165].
6. Conclusions
NAFLD is an alarming health issue that is occurring with rising frequency in developed
countries. It is now well documented that PPARβ/δ is involved in regulating glucose and lipid
metabolism in the liver. An improved understanding of the physiological roles of PPARs, particularly
PPARβ/δ, will likely contribute to the design and development of safe agonists with enhanced
therapeutic potential compared to first-generation agonists. Although much remains unknown about
the physiological impact of PPARβ/δ, prior research has elucidated highly interesting NAFLD-related
functions, as reviewed in this article.
Some results on PPARβ/δ roles seem contradictory, and the reasons for these discrepancies is
unclear. It is conceivable that PPARβ/δ exert different functions in a context- and agonist-specific
manner. For example, one study reported that PPARβ/δ stimulates the de novo lipogenesis
pathway, which is accompanied by lipid deposition. Interestingly, this PPARβ/δ-regulated lipogenic
program is paralleled by reduced JNK stress signaling, suggesting that it may protect against
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lipotoxicity [28]. However, it has also been suggested that PPARβ/δ suppresses hepatic lipogenesis.
PPARβ/δ overexpression enhanced Insig-1 expression, which suppressed SREBP-1 activation and
thus ameliorated hepatic steatosis in obese db/db mice [134]. Similarly, PPARβ/δ agonists GW501516
and KD3010 exerted pro-fibrotic and anti-fibrotic effects, respectively, in CCl4-injured livers [145,146].
Uncovering the causes for these apparent discrepancies will likely elucidate differentiated responses of
PPARβ/δ in specific situations, which will be important for PPARβ/δ as a pharmacological target. We are
in the opinion that detail transcriptomic profiling in combination with a better understanding of the
pharmacological characteristics of candidate drugs, such as half-life, affinity constant, and bioavailability,
may provide insights into their true target and reveal potential off-target effects.
PPARβ/δ also plays an interesting role in the alternative activation of Kupffer cells to
the anti-inflammatory macrophage M2 subtype [143], revealing the direct PPARβ/δ-dependent
involvement of Kupffer cells in liver lipid metabolism. Based on this beneficial role for alternatively
activated Kupffer cells in metabolic syndrome conditions, controlling PPARβ/δ activity in these cells
may contribute to delaying NAFLD progression.
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The fine tuning of PPAR-regulated physiological functions in the liver and other organs is
influenced by the functional interaction between PPARβ/δ and PPARα [121,131]. PPARβ/δ apparently
works upstream of PPARα, controlling the production of MUFAs, as well as PC (18:0/18:1), which activates
muscle PPARα to increase muscle energy use [121]. MUFAs also activate PPARα in the liver itself.
This regulatory circuit couples ligand production and the activities of two receptors that play key roles
in liver energy metabolism.
These complex interactions are certainly of interest for the development of novel PPAR drugs.
PPARα/PPARβ/δ dual agonists may have additional beneficial effects due to the integrated
roles of these two receptors through the abovementioned regulatory circuit they form together.
GFT505 (elafibranor) is the most advanced PPARα/PPARβ/δ dual agonist [158]. It has been tested in
several clinical trials and is currently being evaluated in a clinical phase III study [166]. Several other
PPAR agonists, dual agonists, and pan-agonists of interest have been investigated, and some are now
in clinical studies of safety and efficacy (Figure 4). As PPARs play important roles in regulating genes
involved in fatty acid uptake and oxidation [65–67], we propose that targeting PPARs will be one of
the best possibilities to treat fatty liver diseases.
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IL interleukin
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NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NCAN neurocan
NCoR nuclear receptor corepressor
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells
NTD N-terminal domain
PC Phosphatidylcholine
Pdcd1lg2 programmed cell death 1 ligand 2
PKM2 M2 isoform of pyruvate kinase
PNAPL3 patatin-like phospholipase domain containing 3
PPAR peroxisome proliferator-activated receptor
PPP1R3B protein phosphatase 1 regulatory subunit 3B
PPRE peroxisome proliferator response element
PTEN phosphatase and tensin homolog deleted on chromosome 10
RXR retinoic acid receptor
SCD1 stearoyl-CoA desaturase 1
SMRT silencing mediator of retinoid and thyroid receptors
SREBP1c sterol-regulated binding protein 1c
STAT3 signal transducer and activator of transcription 3
TF transcription factor
TFBS TF-binding site
TM6SF2 transmembrane 6 superfamily member 2
TNFα tumor necrosis factor α
TZD thiazolidinedione
VCAM-1 vascular cell adhesion molecule-1
VLDL very low-density lipoprotein
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